New Guidelines for Treatment of Hypertension (JNC8)
Satish Kumar, MD, Professor, Department of Medicine/Nephrology
Upon completion of this activity, participants will be able to: Describe the new guidelines for treatment of hypertension from JNC8. To distinguish blood pressure goals for the general population, the elderly and patients with diabetes and with chronic kidney disease. To identify appropriate first and second line drugs for treatment of hypertension.
Disclosure Report: Course Director: Dr. Michael Bronze has no financial relationships or affiliations to disclose. Planning Committee Members: Dr. Ben Cowley has been a consultant for Otsuka. Dr. Courtney Houchen has grants/research support in that he is the Co-Founder of COARE Biotechnology. Dr. James Lane has received grants/research support from Novo Nordisk, VM BioPharma, EMD Serono, Inc, Merck Sharp & Dohme Corp, Eli Lilly and Company, Sanofi-Aventis, Merck/Pfizer, and Genkyotex. Dr. Dwight Reynolds has received grants/research support from Medtronic. He has been a consultant for Medtronic. He has received honorarium from Medtronic. Dr. Ming Zou has grants/research support from NIH and AHA. Drs. Rhett Jackson, Adam Asch, Douglas Drevets, Brent Brown, and Mary Beth Humphrey have no financial relationships or affiliations to disclose. Course Contact: Ms. Brenda Wilkerson has no financial relationships or affiliations to disclose. Speakers: Dr. Abu-Fadel has received honorarium form Abbott Vascular. : Dr. Kumar has no financial relationships or affiliations to disclose.
Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability. Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
For further information contact:
271-6651 ext. 54374